Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2
文献类型：期刊论文
| 作者 | Xie, Yongsheng2; Li, Bo1; Bu, Wenxuan2; Gao, Lu2; Zhang, Yong1; Lan, Xiucai2; Hou, Jun2; Xu, Zhijian1 ; Chang, Shuaikang2; Yu, Dandan2
|
| 刊名 | INTERNATIONAL JOURNAL OF ONCOLOGY
 |
| 出版日期 | 2018-08 |
| 卷号 | 53期号:2页码:823-834 |
| 关键词 | mantle cell lymphoma dihydrocelastrol apoptosis cell cycle mTORC1 mTORC2 |
| ISSN号 | 1019-6439 |
| DOI | 10.3892/ijo.2018.4438 |
| 文献子类 | Article |
| 英文摘要 | Mantle cell lymphoma (MCL) is a distinct and highly aggressive subtype of B-cell non-Hodgkin lymphoma. Dihydrocelastrol (DHCE) is a dihydro-analog of celastrol, which is isolated from the traditional Chinese medicinal plant Tripterygium wilfordii. The present study aimed to investigate the effects of DHCE treatment on MCL cells, and to determine the mechanism underlying its potent antitumor activity in vitro and in vivo using the Cell Counting kit-8 assay, clonogenic assay, apoptosis assay, cell cycle analysis, immunofluorescence staining, western blotting and tumor xenograft models. The results demonstrated that DHCE treatment exerted minimal cytotoxic effects on normal cells, but markedly suppressed MCL cell proliferation by inducing G(0)/G(1) phase cell cycle arrest, and inhibited MCL cell viability by stimulating apoptosis via extrinsic and intrinsic pathways. In addition, the results revealed that DHCE suppressed cell growth and proliferation by inhibiting mammalian target of rapamycin complex (mTORC)1-mediated phosphorylation of ribosomal protein S6 kinase and eukaryotic initiation factor 4E binding protein. Simultaneously, DHCE induced apoptosis and inhibited cell survival by suppressing mTORC2-mediated phosphorylation of protein kinase B and nuclear factor-B activity. In addition to in vitro findings, DHCE treatment reduced the MCL tumor burden in a xenograft mouse model, without indications of toxicity. Furthermore, combined treatment with DHCE and bortezomib, a proteasome inhibitor, induced a synergistic cytotoxic effect on MCL cells. These findings indicated that DHCE may have the potential to serve as a novel therapeutic agent for the treatment of MCL through dually inhibiting mTORC1 and mTORC2. |
| WOS关键词 | NF-KAPPA-B ; SINGLE-AGENT TEMSIROLIMUS ; CANCER DEVELOPMENT ; PATHWAY ; ACTIVATION ; APOPTOSIS ; PROGRESSION ; CELASTROL ; MALIGNANCIES ; THERAPY |
| 资助项目 | National Natural Science Foundation of China[81570190] ; National Natural Science Foundation of China[81529001] ; National Natural Science Foundation of China[81670194] ; National Natural Science Foundation of China[81602515] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000440581500032 |
| 出版者 | SPANDIDOS PUBL LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/279646]  |
| 专题 | 药物发现与设计中心 |
| 通讯作者 | Zhu, Weiliang; Shi, Jumei |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China; 2.Tongji Univ, Shanghai Peoples Hosp 10, Dept Hematol, Sch Med, 301 Yanchang Rd, Shanghai 200072, Peoples R China; 3.Tongji Univ, Canc Ctr, Dept Hematol, Shanghai 200092, Peoples R China |
| 推荐引用方式 GB/T 7714 | Xie, Yongsheng,Li, Bo,Bu, Wenxuan,et al. Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2[J]. INTERNATIONAL JOURNAL OF ONCOLOGY,2018,53(2):823-834. |
| APA | Xie, Yongsheng.,Li, Bo.,Bu, Wenxuan.,Gao, Lu.,Zhang, Yong.,...&Shi, Jumei.(2018).Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2.INTERNATIONAL JOURNAL OF ONCOLOGY,53(2),823-834. |
| MLA | Xie, Yongsheng,et al."Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2".INTERNATIONAL JOURNAL OF ONCOLOGY 53.2(2018):823-834. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。